AHA Scientific Sessions 2023 Late-Breaking Science Coverage

Published: 30 October 2023

  • Views:

    Views Icon 2000
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.

 

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of cardiovascular innovation, they offer concise perspectives on late-breaking data.

 

Dr Harriette Van Spall returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

 

Watch our Expert interviews for late-breaking science methodology, results and implications for practice and research in under 10 minutes.

 

Delve into the personal motivations of some of the investigators, and gain valuable insights and advice for early career researchers in our Behind the Heart series. These short videos offer an opportunity to look beyond scientific achievements and connect on a more personal level.

More from this programme

Part 1

View from the Thoraxcenter

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. 

Part 2

Late-Breaker Discussions with Harriette Van Spall

Dr Harriette Van Spall, recipient of 2022's AHA Dr. Nanette K. Wenger Award, returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

About the episode

AHA 23 — In this brief interview, we are joined by Prof Charalambos Antoniades (Oxford University, UK) to discuss the ORFAN trial, sponsored by the University of Oxford.

ORFAN is a prospective, multicenter, observational study that collected CT scans, biological material and outcomes data to develop and validate biomarkers of cardiometabolic risk. The registry included 250000 unselected consecutive patients at participating centres. The study combines imaging data and patient demographics to improve new or existing image analysis algorithms and software tools.

Findings showed that in patients undergoing CTCA had 2x more heart attacks and cardiac deaths in those without obstructive CAD a compared to those with obstructive CAD. Measuring coronary inflammation predicts fatal and non-fatal cardiac events independent from clinical risk scores and CT interpretation. New AI-driven risk classification changes risk-driven management in 40% of patients.

Questions:

  1. What is the aim of the ORFAN registry?
  2. Can you tell us about the AI algorithm used in this study?
  3. What was the study design and the baseline characteristics of the study cohort?
  4. What are the findings?
  5. What conclusions can be made? What are the limitations of this registry?
  6. What advancements can we expect in the next 5 years as AI continues to impact the field of medicine?

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Interviewer: Mirjam Boros
Editor: Jordan Rance
Video Specialist: Dan Brent

Faculty Biographies

Charalambos Antoniades

Charalambos Antoniades

Deputy Head, Division of Cardiovascular Medicine

Prof Charalambos Antoniades is a full Professor of Cardiovascular Medicine at the University of Oxford, and a Consultant Cardiologist in Oxford University Hospitals. 

Prof Antoniades graduated Medicine in Athens Medical School a with hons (top 3%) in 2000 and was awarded his PhD title with hons on the genetics of premature myocardial infarction. He won multiple prestigious international Young Investigator award competitions and has published  250 scientific papers and in 2016 he received the outstanding achievement award of the European Society of Cardiology. He is also deputy editor of Cardiovascular Research, editor of British Journal of Pharmacology and associate editor of other journals. He is board member of the British Atherosclerosis Society and one of the founders of the ESC Scientists of Tomorrow.

Prof Antoniades is founder and Chief Scientific Officer of Caristo Diagnostics, a university of Oxford spinout company commercialising novel CT-derived biomarkers…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.